Showing results (161-170 of 183) with videos related to
Sort By:
Pageof 19
NPJ Breast Cancer|June 27, 2017
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer riskThomas P Slavin, Kara N Maxwell, Jenna Lilyquist, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Colorectal cancer screeningRandall W Burt, Jamie A Cannon, Donald S David, et al.Biorxiv : the Preprint Server for Biology|January 13, 2025
VISTA-induced tumor suppression by a four amino acid intracellular motifYan Zhao, Tina Andoh, Fatima Charles, et al.Cancer Research|July 14, 2025
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor SuppressionYan Zhao, Tina Andoh, Fatima Charles, et al.JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in OncologyDawn Provenzale, Samir Gupta, Dennis J Ahnen, et al.JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.JCO Precision Oncology|September 21, 2020
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary CancersKara N Maxwell, Brandon M Wenz, Abha Kulkarni, et al.Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.Pageof 19